Solving a Mystery Using PBPK: How Drug-excipient Complexes Can Confound a Metabolic DDI Result

Assessment of drug-drug interaction (DDI) liabilities is an important safety component of any drug development program. Itraconazole, a selective strong inhibitor of CYP3A, has been widely employed to determine the maximum drug interaction risk with new molecular entities as CYP3A substrates. Hydroxypropyl-β-cyclo-dextrin (HP-β-CD) is used as an excipient in the itraconazole solution for oral dosing … Continued

1 of 1
Back to top
Powered by GlobalLink OneLink Software